Bacilli bacterium VT-13-104 in Patients with Gastrointestinal Cancer
Given previous evidence that gut microbes contribute to cancer development, the presence of a commensalistic bacterial species in patients with duodenal cancer may hint at a role for this organism in gastrointestinal cancer progression. In recent work, we identified one such bacterium: Bacilli bacterium VT-13-104. This organism is a novel species that was isolated from the intestine of a patient with duodenal cancer. Genetic analyses indicated that Bacilli bacterium VT-13-104 harbors numerous antibiotic resistance genes, as well as various toxin-encoding genes, including hemolysin and numerous peptidases. Furthermore, the organism produces spores that are impervious to antibiotics. As such, these antimicrobials are not sufficient to eliminate this bacterium from a site of infection. Additional studies are therefore warranted to examine the role of this species in gastrointestinal diseases.
In future research, we intend to determine the prevalence of Bacilli bacterium VT-13-10 among different cancer patient groups, as well as in healthy individuals and in persons suffering from other microbiota-associated diseases.
Tetz, G., & Tetz, V. (2015). Complete genome sequence of Bacilli bacterium strain VT-13- 104 isolated from the intestine of a patient with duodenal cancer.Genome announcements, 3(4), e00705-15.